In the hepatitis B vaccination programme, the efficacy of the vaccine is determined by checking anti-HBs antibody titer 1 month after the third dose. The protective antibody level is considered adequate if anti-HBs is:

• A ≥ 1 IU/L
• B ≥ 50 IU/L
• C ≥ 10 IU/L ✓
• D ≥ 100 IU/L

Explanation

An anti-HBs titre of ≥10 mIU/mL (equivalent to ≥10 IU/L) measured 1–2 months after completion of the hepatitis B vaccine series is considered a seroprotective response, indicating adequate immunity. Levels below 10 mIU/mL are considered non-protective; such individuals should receive a repeat 3-dose series and be re-tested. Levels between 1–10 mIU/mL are considered poor responders. This threshold is used in occupational health settings (healthcare workers) and post-exposure prophylaxis decisions. Anti-HBs ≥100 mIU/mL are considered high-level responders with long-term protection.

Reference: Park's Textbook of Preventive and Social Medicine, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.